Search T Helper/CD4+ T-Cell Epitope Database

Found 16 matching records:

Displaying record number 201623

Download this epitope record as JSON.

HXB2 Location	Pol(109-131) Protease(53-75) DNA(2409..2477)	Pol Epitope Map
Author Location	Protease(53-75 M)
Epitope	`FIKVRQYDQILIEICGKKAIGTV`	Epitope Alignment
Epitope Name	Protease(53-75)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Patient MHC/HLA	DPA102:01, DPB101:01; DQA101:02, DQB105:02; DPA101:03, DPB102:01; DPA101:03, DPB103:01; DPA101:03, DPB104:01; DPA103:01, DPB104:02; DPB102:01, DPB105:01; DPA101:03, DPB120:01; DQA103:01, DQB103:01; DQA101:01, DQB105:01
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	subtype comparisons, computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, FIKVRQYDQILIEICGKKAIGTV, binds 13/17 (76%) HLA-DR, 3/11 (27%) HLA-DQ and 7/8 (88%) HLA-DP tested. It was recognized by 1/9 patients carrying an HIV-1 BF recombinant.
In vitro binding assays show that epitope Protease(53-75) binds the following HLA: DP, DQ, DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0405, DRB1*0802, DRB1*0901, DRB1*1001, DRB1*1201, DRB1*1601, DRB1*1602, DRB3*0101, DRB4*0101, DRB6*0101; I-A^b, I-A^d.

References

Almeida2012 Rafael Ribeiro Almeida, Daniela Santoro Rosa, Susan Pereira Ribeiro, Vinicius Canato Santana, Esper Georges Kallás, John Sidney, Alessandro Sette, Jorge Kalil, and Edecio Cunha-Neto. Broad and Cross-Clade CD4+ T-Cell Responses Elicited by a DNA Vaccine Encoding Highly Conserved and Promiscuous HIV-1 M-Group Consensus Peptides. PLoS One, 7(9):e45267, 2012. PubMed ID: 23028895. Show all entries for this paper.

Displaying record number 201627

Download this epitope record as JSON.

HXB2 Location	Pol(135-151) Protease(79-95) DNA(2487..2537)	Pol Epitope Map
Author Location	Protease(79-95 M)
Epitope	`PTPVNIIGRNMLTQIGC`	Epitope Alignment
Epitope Name	Protease(79-95)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Patient MHC/HLA	DPA101:03, DPB102:01; DPA101:03, DPB103:01; DPA101:03, DPB104:01; DPA103:01, DPB104:02
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, PTPVNIIGRNMLTQIGC, binds 6/17 (35%) HLA-DR, 0/11 (0%) HLA-DQ and 4/8 (50%) HLA-DP tested.
In vitro binding assays show that epitope Protease(79-95) binds the following HLA: DP, DQ, DRB1*0101, DRB1*0401, DRB1*0405, DRB1*1302, DRB3*0101, DRB4*0101; I-A^b, I-A^d.

References

Displaying record number 201628

Download this epitope record as JSON.

HXB2 Location	Pol(498-512) RT(343-357) DNA(3576..3620)	Pol Epitope Map
Author Location	RT(343-357 M)
Epitope	`QEPFKNLKTGKYAKM`	Epitope Alignment
Epitope Name	RT(343-357)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Patient MHC/HLA	DPA102:01, DPB101:01; DPA101:03, DPB102:01; DPA101:03, DPB104:01
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	subtype comparisons, computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, QEPFKNLKTGKYAKM, binds 11/17 (65%) HLA-DR, 0/11 (0%) HLA-DQ and 3/8 (38%) HLA-DP tested. It was recognized by 4/9 patients carrying HIV-1 BF recombinants.
In vitro binding assays show that epitope RT(343-357) binds the following HLA: DP, DQ, DRB1*0101, DRB1*0401, DRB1*0405, DRB1*0802, DRB1*0901, DRB1*1001, DRB1*1101, DRB1*1201, DRB1*1601, DRB1*1602, DRB6*0101; I-A^b, I-A^d.

References

Displaying record number 201629

Download this epitope record as JSON.

HXB2 Location	Pol(509-523) RT(354-368) DNA(3609..3653)	Pol Epitope Map
Author Location	Protease(354-368 M)
Epitope	`YAKMRSAHTNDVKQL`	Epitope Alignment
Epitope Name	Protease(354-368)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Patient MHC/HLA	DPA101:03, DPB102:01; DPA102:01, DPB114:01; DPA101:03, DPB120:01; DQA103:01, DQB103:01; DQA101:02, DQB106:02; DQA101:03, DQB106:03
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	subtype comparisons, computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, YAKMRSAHTNDVKQL, binds 12/17 (71%) HLA-DR, 4/11 (37%) HLA-DQ and 3/8 (38%) HLA-DP tested. It was not recognized by any of 9 patients carrying an HIV-1 BF recombinant.
In vitro binding assays show that epitope Protease(354-368) binds the following HLA: DP, DQ, DRB1*0101, DRB1*0401, DRB1*0405, DRB1*0701, DRB1*0802, DRB1*0901, DRB1*1001, DRB1*1302, DRB1*1601, DRB1*1602, DRB4*0101, DRB6*0101; I-A^b, I-A^d.

References

Displaying record number 201630

Download this epitope record as JSON.

HXB2 Location	Pol(524-546) RT(369-391) DNA(3654..3722)	Pol Epitope Map
Author Location	Protease(369-391 M)
Epitope	`TEAVQKIATESIVIWGKTPKFRL`	Epitope Alignment
Epitope Name	RT(369-391)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Patient MHC/HLA	DPB102:01, DPB105:01; DPA102:01, DPB114:01; DPA101:03, DPB120:01; DQA102:01, DQB102:02; DQA101:03, DQB106:03; DQA101:01, DQB105:01
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	subtype comparisons, computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, TEAVQKIATESIVIWGKTPKFRL, binds 12/17 (71%) HLA-DR, 2/11 (18%) HLA-DQ and 3/8 (38%) HLA-DP tested. It was recognized by 2/14 patients carrying a subtype B HIV-1, and elicits an immune response in BALB/c mice as well as CD4+ and CD8+ proliferation.
In vitro binding assays show that epitope RT(369-391) binds the following HLA: DP, DQ, DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*0802, DRB1*0901, DRB1*1001, DRB1*1201, DRB1*1601, DRB1*1602, DRB3*0202, DRB6*0101; I-A^b, I-A^d.

References

Displaying record number 201631

Download this epitope record as JSON.

HXB2 Location	Pol(568-582) RT(413-427) DNA(3786..3830)	Pol Epitope Map
Author Location	Protease(413-427 M)
Epitope	`EWEFVNTPPLVKLWY`	Epitope Alignment
Epitope Name	Protease(413-427)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Patient MHC/HLA	DPA102:01, DPB101:01; DPA101:03, DPB102:01; DPA101:03, DPB104:01; DPA101:03, DPB120:01; DQA105:01, DQB102:01; DQA101:01, DQB105:01
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	subtype comparisons, computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, EWEFVNTPPLVKLWY, binds 14/17 (83%) HLA-DR, 1/11 (9%) HLA-DQ and 4/8 (50%) HLA-DP tested. It was recognized by 1/9 patients carrying an HIV-1 BF recombinant and elicits immune response in BALB/c mice as well as CD4+ and CD8+ proliferation.
Subtype-specific variants of epitope EWEFVNTPPLVKLWY are dWEFVNTPPLVKLWY (A1 subtype), EWEFVsTPPLVKLWY (B subtype), EWEFiNTPPLVKLWY (C subtype) and EWEyVNTPPLVKLWY (D subtype).
In vitro binding assays show that epitope Protease(413-427) bind the following HLA: DP, DQ, DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0405, DRB1*0802, DRB1*0901, DRB1*1001, DRB1*1201, DRB1*1601, DRB1*1602, DRB3*0101, DRB4*0101, DRB6*0101, I-A^b, I-A^d.

References

Displaying record number 201632

Download this epitope record as JSON.

HXB2 Location	Pol(586-600) RT(431-445) DNA(3840..3884)	Pol Epitope Map
Author Location	Protease(431-445 M)
Epitope	`KEPIVGAETFYVDGA`	Epitope Alignment
Epitope Name	Protease(431-445)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Patient MHC/HLA	DPA102:01, DPB101:01; DQA101:04, DQB105:03; DQA101:02, DQB106:02; DQA101:03, DQB106:03; DPA101:03, DPB102:01; DPA101:03, DPB104:01; DPA103:01, DPB104:02; DQA105:01, DQB102:01; DQA102:01, DQB102:02; DQA103:01, DQB103:01; DQA105:01, DQB103:01; DQA104:01, DQB104:02
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	subtype comparisons, computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, KEPIVGAETFYVDGA, binds 16/17 (94%) HLA-DR, 8/11 (73%) HLA-DQ and 3/8 (38%) HLA-DP tested. It was recognized by 1/14 patients carrying B subtype HIV-1.
In vitro binding assays show that epitope Protease(431-445) binds the following HLA: DP, DQ, DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0405, DRB1*0701, DRB1*0802, DRB1*0901, DRB1*1001, DRB1*1201, DRB1*1302, DRB1*1601, DRB1*1602, DRB3*0101, DRB3*0202, DRB4*0101, DRB6*0101, I-A^b, I-A^d.

References

Displaying record number 201654

Download this epitope record as JSON.

HXB2 Location	Pol(683-701) RT(528-546) DNA(4131..4187)	Pol Epitope Map
Author Location	RT(528-546 M)
Epitope	`KEKVYLSWVPAHKGIGGNE`	Epitope Alignment
Epitope Name	RT(528-546)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Patient MHC/HLA	DPA102:01, DPB101:01; DPA101:03, DPB102:01; DPA101:03, DPB103:01; DPA103:01, DPB104:02; DPA101:03, DPB120:01; DQA103:01, DQB103:01; DQA105:01, DQB103:01; DQA101:02, DQB106:02; DQA101:03, DQB106:03
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	subtype comparisons, computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, KEKVYLSWVPAHKGIGGNE, binds 15/17 (88%) HLA-DR, 4/11 (36%) HLA-DQ and 5/8 (63%) HLA-DP tested; and elicits immune response in BALB/c mice as well as CD4+ and CD8+ proliferation.
Subtype-specific variants of KEKVYLSWVPAHKGIGGNE were KdKVYLSWVPAHKGIGGNE (subtype A1), KEKVYLaWVPAHKGIGGNE (subtype B), KErVYLSWVPAHKGIGGNE (subtype C), KEKiYLSWVPAHKGIGGNE (subtype F1) and KEKVYLtWVPAHKGIGGNE (subtype G).
In vitro binding assays show that epitope RT(528-546) binds the following HLA: DP, DQ, DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0405, DRB1*0701, DRB1*0802, DRB1*0901, DRB1*1001, DRB1*1101, DRB1*1601, DRB1*1602, DRB3*0101, DRB3*0202, DRB4*0101, DRB6*0101; I-A^b, I-A^d.

References

Displaying record number 201655

Download this epitope record as JSON.

HXB2 Location	Pol(743-758) Integrase(28-43) DNA(4311..4358)	Pol Epitope Map
Author Location	Integrase(28-43 M)
Epitope	`LPPIVAKEIVASCDKC`	Epitope Alignment
Epitope Name	Integrase(28-43)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Patient MHC/HLA	DPA101:03, DPB102:01; DPA103:01, DPB104:02; DPA101:03, DPB120:01; DQA103:01, DQB103:01
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	subtype comparisons, computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, LPPIVAKEIVASCDKC, binds 7/17 (41%) HLA-DR, 1/11 (9%) HLA-DQ and 3/8 (38%) HLA-DP tested. It was recognized by 4/9 patients carrying an HIV-1 BF recombinant.
In vitro binding assays show that epitope Integrase(28-43)) binds the following HLA: DP, DQ, DRB1*0101, DRB1*0401, DRB1*0802, DRB1*1001, DRB1*1101, DRB4*0101, DRB6*0101; I-A^b, I-A^d.

References

Displaying record number 201656

Download this epitope record as JSON.

HXB2 Location	Pol(784-800) Integrase(69-85) DNA(4434..4484)	Pol Epitope Map
Author Location	Integrase(69-85 M)
Epitope	`EGKIILVAVHVASGYIE`	Epitope Alignment
Epitope Name	Integrase(69-85)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Patient MHC/HLA	DPA101:03, DPB102:01; DPA103:01, DPB104:02; DPA101:03, DPB120:01; DQA103:01, DQB103:01; DQA101:01, DQB105:01; DQA101:02, DQB105:02; DQA101:04, DQB105:03; DQA101:02, DQB106:02
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	subtype comparisons, computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, EGKIILVAVHVASGYIE, binds 13/17 (77%) HLA-DR, 5/11 (46%) HLA-DQ and 3/8 (38%) HLA-DP tested. It was recognized by 1/14 patients carrying HIV-1 B subtype.
In vitro binding assays show that epitope Integrase(69-85) bind the following HLA: DP, DQ, DRB1*0101, DRB1*0401, DRB1*0405, DRB1*0701, DRB1*0802, DRB1*0901, DRB1*1001, DRB1*1101, DRB1*1601, DRB1*1602, DRB3*0101, DRB4*0101, DRB6*0101; I-A^b, I-A^d.

References

Displaying record number 201657

Download this epitope record as JSON.

HXB2 Location	Pol(811-828) Integrase(96-113) DNA(4515..4568)	Pol Epitope Map
Author Location	Integrase(96-113 M)
Epitope	`ETAYFILKLAGRWPVKVI`	Epitope Alignment
Epitope Name	Integrase(96-113)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Patient MHC/HLA	DPA102:01, DPB101:01; DQA101:02, DQB106:02; DPA101:03, DPB102:01; DPA101:03, DPB104:01; DPA103:01, DPB104:02; DPB102:01, DPB105:01; DPA101:03, DPB120:01; DQA101:01, DQB105:01; DQA101:02, DQB105:02; DQA101:04, DQB105:03
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	subtype comparisons, computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, ETAYFILKLAGRWPVKVI, binds 11/17 (65%) HLA-DR, 4/11 (37%) HLA-DQ and 6/8 (75%) HLA-DP tested. It was recognized by 2/9 patients carrying an HIV-1 BF recombinant, 3/14 patients with B subtype, 1/1 BC recombinant-carrying patient and 1/1 patient infected with F subtype HIV-1. Integrase(96-113) elicits immune response in BALB/c mice.
In vitro binding assays show that epitope Integrase(96-113) binds the following HLA: DP, DQ, DRB1*0101, DRB1*0301, DRB1*0405, DRB1*0802, DRB1*0901, DRB1*1001, DRB1*1101, DRB1*1601, DRB1*1602, DRB3*0101, DRB6*0101; I-A^b, I-A^d.

References

Displaying record number 201706

Download this epitope record as JSON.

HXB2 Location	Pol(931-950) Integrase(216-235) DNA(4875..4934)	Pol Epitope Map
Author Location	Integrase(216-235 M)
Epitope	`QITKIQNFRVYYRDSRDPIW`	Epitope Alignment
Epitope Name	Integrase(216-235)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Patient MHC/HLA	DPA101:03, DPB103:01; DPB102:01, DPB105:01; DQA101:03, DQB106:03
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	subtype comparisons, computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, QITKIQNFRVYYRDSRDPIW, binds 15/17 (88%) HLA-DR, 4/11 (37%) HLA-DQ and 7/8 (87.5%) HLA-DP tested. It was recognized by 1/14 patients with B subtype infection; and elicits immune response in BABL/c mice as well as CD4+ and CD8+ proliferation.
Subtype-specific variants of QITKIQNFRVYYRDSRDPIW were QITKIQNFRVYYRDSRDPlW (subtype A1), QITKIQNFRVYYRDnRDPlW (subtype B), QIiKIQNFRVYYRDSRDPIW (subtype C), QIiKIQNFRVYYRDSRDPvW (subtype D), QITKIQNFRVYYRDSRDPvW (subtype F1) and QITKIQNFRVYfRDSRDPIW (subtype G).
In vitro binding assays show that epitope Integrase(216-235) bind the following HLA: DP, DQ, DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0406, DRB1*0701, DRB1*0802, DRB1*0901, DRB1*1001, DRB1*1101, DRB1*1201, DRB1*1601, DRB1*1602, DRB3*0101, DRB3*0202, DRB6*0101; and I-A^b or I-A^d.

References

Displaying record number 201704

Download this epitope record as JSON.

HXB2 Location	Pol(964-983) Integrase(249-268) DNA(4974..5033)	Pol Epitope Map
Author Location	Integrase(249-268 M)
Epitope	`VVIQDNSDIKVVPRRKAKII`	Epitope Alignment
Epitope Name	Integrase(249-268)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Patient MHC/HLA	DPA101:03, DPB103:01; DPB102:01, DPB105:01; DQA101:03, DQB106:03
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	subtype comparisons, computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, VVIQDNSDIKVVPRRKAKII, binds 9/17 (63%) HLA-DR, 1/11 (9%) HLA-DQ and 2/8 (25%) HLA-DP tested.
In vitro binding assays show that epitope Integrase(249-268) binds the following HLA: DP, DQ, DRB1*0101, DRB1*0301, DRB1*0802, DRB1*1001, DRB1*1101, DRB1*1601, DRB1*1602, DRB4*0101, DRB6*0101; I-A^b, I-A^d.

References

Displaying record number 201705

Download this epitope record as JSON.

HXB2 Location	Vpu(13-26) DNA(6098..6139)	Vpu Epitope Map
Author Location	Vpu(53-75 M)
Epitope	`IVALIIAIVVWTIV`	Epitope Alignment
Epitope Name	Vpu(13-26)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	subtype comparisons, computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, IVALIIAIVVWTIV, binds 2/17 (12%) HLA-DR, 0/11 (0%) HLA-DQ and 0/8 (0%) HLA-DP tested.
In vitro binding assays show that epitope Vpu(13-26) binds the following HLA: DP, DQ, DRB1*0101, DRB1*0802; I-A^b, I-A^d.

References

Displaying record number 201658

Download this epitope record as JSON.

HXB2 Location	Nef(67-87) DNA(8995..9057)	Nef Epitope Map
Author Location	Nef(67-87 M)
Epitope	`GFPVRPQVPLRPMTYKGAFDL`	Epitope Alignment
Epitope Name	Nef(67-87)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Patient MHC/HLA	DPA101:03, DPB102:01; DPA101:03, DPB103:01; DPA103:01, DPB104:02; DQA103:01, DQB103:01
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	subtype comparisons, computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, GFPVRPQVPLRPMTYKGAFDL, binds 10/17 (59%) HLA-DR, 1/11 (9%) HLA-DQ and 3/8 (38%) HLA-DP tested. It was recognized by 3/9 BF recombinant-, 1/1 BC recombinant-, 3/14 B-subtype- and 1/1 F-subtype-infected patients.
In vitro binding assays show that epitope Nef(67-87) binds the following HLA: DP, DQ, DRB1*0101, DRB1*0401, DRB1*0802, DRB1*0901, DRB1*1001, DRB1*1101, DRB1*1201, DRB1*1601, DRB4*0101, DRB6*0101, I-A^b, I-A^d;

References

Displaying record number 201703

Download this epitope record as JSON.

HXB2 Location	Nef(133-156) DNA(9193..9264)	Nef Epitope Map
Author Location	Nef(133-156 M)
Epitope	`IRYPLTFGWCFKLVPVDPREVEEA`	Epitope Alignment
Epitope Name	Nef(133-156)
Subtype	A1, B, C, D, F1, F2, G, H
Species (MHC/HLA)	human, humanized mouse, mouse
Immunogen	vaccine
Patient MHC/HLA	DPA101:03, DPB102:01; DPA101:03, DPB104:01; DPA103:01, DPB104:02; DQA103:01, DQB103:01; DQA101:01, DQB105:01
Country	Brazil
Experimental methods	CD4 T-cell Elispot - IFNγ, HLA binding, Proliferation
Keywords	subtype comparisons, computational epitope prediction, vaccine-induced immune responses, HLA cross-presentation, vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine component	Gag, Nef, Pol, Rev, Vif, Vpr, Vpu

Notes

A DNA vaccine, HIVBr27, was designed with 27 tandem HLA-DR-binding peptides predicted by the TEPITOPE algorithm, and was used to immunize BALB/c mice. Broad, cross-clade and polyfunctional CD4+ and CTL responses including proliferation and production of IFN-γ, TNF-α were detected against the vaccine in wt and transgenic mice.
Helper epitope, IRYPLTFGWCFKLVPVDPREVEEA, binds 9/17 (53%) HLA-DR, 1/11 (9%) HLA-DQ and 4/8 (50%) HLA-DP tested. It was recognized by 2/9 BF recombinant-, 5/14 B-subtype- and 1/1 F-subtype-infected patients.
In vitro binding assays show that epitope Nef(133-156) binds the following HLA: DP, DQ, DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0405, DRB1*0701, DRB1*0901, DRB1*1001, DRB1*1601, DRB6*0101; I-A^b, I-A^d.